Court Square Capital Partners plans to acquire Center for Vein Restoration (CVR), Healthcare Dealflow is the first to report. The transaction does not appear to have been publicly announced.
Healthcare Dealflow identified the pending acquisition through a Notice of Material Change filed with the Massachusetts Health Policy Commission and signed October 19, 2026.
Under the proposed transaction, CVR Acquisition, LLC, which is indirectly controlled by funds affiliated with Court Square, will acquire CVR Management, LLC from CVR Acquisition Parent, LLC. Financial terms were not disclosed.
Greenbelt, Maryland-based CVR Management is a management services organization that provides non-clinical administrative and back-office support to physician-owned vein care practices across several states. The filing says CVR Management is ultimately owned by an affiliated fund of Cortec Group and certain other investors.
Stay Informed
The Daily Brief covers healthcare M&A deal activity, news, and trends every business day.
Join the investment banks, private equity firms, and advisors who rely on it to stay current.
Subscribe to The Daily Brief →Cortec acquired CVR in January 2016 in partnership with management, marking the first platform investment of its $1.1 billion Fund VI. At the time, CVR provided management services to 43 vein treatment clinics. Today, Center for Vein Restoration says it operates more than 130 locations nationwide.
The Court Square transaction is intended to provide CVR Management with additional capital and resources to support continued growth and expanded access to treatment for venous insufficiency and other vein disorders.
The physician-owned Massachusetts entity that provides clinical care is not part of the transaction. According to the filing, all current Massachusetts locations will remain open and CVR Management will continue providing administrative and management services under its existing arrangement.
The parties do not anticipate changes to reimbursement rates, referral patterns, access to services, quality of care, payer mix, service areas or service lines following the transaction.
The proposed effective date is December 31, 2026. The parties submitted a Hart-Scott-Rodino filing to the Federal Trade Commission on October 16, along with notices to the Washington and Illinois attorneys general. The Massachusetts filing also says the parties planned to submit notice of the transaction to the Oregon Health Authority on or before October 23.
Healthcare Dealflow is a healthcare M&A intelligence platform that tracks deal activity, trends and analysis across the healthcare sector for an audience of private equity firms, investment banks, corporate development teams, and transaction advisors. Subscribe to The Daily Brief here.